According to the new market research report "Cell Therapy Technologies Market by Product (Consumables, Equipment, Software), Cell Type (Human Stem & Differentiated, Animal), Process Stages (Cell Processing, Distribution, Handling, QC), End User, and Region - Global Forecast to 2023",published by MarketsandMarkets™, The global cell therapy technologies market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4% during the forecast period
Browse in-depth TOC on “Cell Therapy Technologies Market"
75 - Table
30 – Figures
116 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978
Rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are the key factors driving the growth of this market. China, India, Japan, Korea, and Brazil are emerging markets for cell therapy instruments.
Cell processing segment to witness the highest growth during the forecast period :
Based on process, the cell therapy technologies market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest market share in 2018 and is projected to witness the highest CAGR during the forecasted period.
To Get Sample Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978
North America to dominate the cell therapy technologies market during the forecast period
The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market in 2018 owing to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.
Key players in this market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).
The drug screening market was valued at USD 4.86 Billion in 2016 and is expected to reach USD 8.63 Billion by 2022, growing at a CAGR of 10.2% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.
Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) - Global Forecast to 2022
Target Audience for this Report:
⏩ Drug and alcohol testing laboratories
⏩ Drug and alcohol testing product manufacturing companies
⏩ Rapid drug screening device manufacturers
⏩ Law enforcement agencies
⏩ Healthcare providers
Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773
Based on product, the market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2017.
The global market by sample type is segmented into urine, breath, oral fluid, hair, and other samples. The urine sample segment is estimated to account for the largest share in 2017, however, the oral fluid samples segment is expected to register the highest growth rate during the forecast period.
Request for Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773
The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.
Key Market Players
Prominent players offering products for drug screening include Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (US). On the other hand, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada), are key players in the market.
Market growth can be attributed to the growing need to curtail escalating healthcare costs, shift from inpatient to outpatient surgical procedures, and growing demand for IT solutions such as mhealth, telehealth, and remote patient monitoring for better management. However, high deployment costs and reluctance among end users to adopt new methods are expected to restrain the overall market growth to a certain extent during the forecast period.
The Ambulatory surgical centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020, at a CAGR of 27.6% during the forecast period
A majority of this growth is attributed to the growing need to curtail escalating healthcare costs, shift from inpatient to outpatient surgical procedures, growing demand for IT solutions such as mhealth, telehealth, and remote patient monitoring for better management, and the need to improve the quality of healthcare while maintaining the operational efficiency of healthcare organizations.
Browse 112 market data Tables and 36 Figures spread through 176 Pages and in-depth TOC
Download PDF Brochure Now: https://www.marketsandmarkets.com/requestsampleNew.asp?id=182183086
Ambulatory Surgery Center Market DRIVERS :
Based on specialty, the Ambulatory surgical centers market is segmented into single and multi-specialty. In 2019, the multi-specialty segment accounted for the largest share of the Ambulatory surgical centers market. The large share of this segment can be attributed to the large number of surgical procedures performed in these facilities and the availability of reimbursement for these procedures.
Request Sample Report of Ambulatory Surgery Centre Market : https://www.marketsandmarkets.com/requestsampleNew.asp?id=182183086
Regional Growth, Development and Demand Analysis:
North America accounted for the largest share of the Ambulatory Surgery Centers Market, followed by Europe. The large share of this region can be attributed to the high adoption of Ambulatory surgical centers for reducing the soaring healthcare costs, increasing volume of surgical procedures performed, and the presence of significant market players, such as Epic Systems Corporation (US), Cerner Corporation (US), McKesson Corporation (US), Philips Healthcare (Netherlands), and Allscripts Healthcare Solutions, Inc. (US).
Key Market Players
Cerner Corporation (US), McKesson Corporation (US), Allscripts Healthcare Solutions, Inc. (US), GE Healthcare (US), Philips Healthcare (Netherlands), athenahealth, Inc. (US), Optum (US), Epic Systems Corporation (US), Medical Information Technology, Inc. (MEDITECH) (US), eClinicalWorks (US), athenahealth, Inc. (US), Advanced Data Systems Corporation (US), NextGen Healthcare (US), CureMD (US), HST Pathways (US), and Surgical Information Systems (US).
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.
Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) – Global Forecast to 2022
Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589
By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period
Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.
By technology, DNA sequencing & next-generation sequencing (NGS) segment to record the highest CAGR during the forecast period
Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.
Request for Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589
North America to account for the largest market size during the forecast period
North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
Key Market Players
The prominent players in this market areAbbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific
Critical questions the report answers:
Get More Information @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=116764589
In cancer research, primary cells are often exposed to heavy radiation doses, chemicals, and viruses, which transforms these cells into cancer cells through genetic mutations and the introduction of oncogenes. In this way, the molecular-level mechanism and cause of cancer, as well as the altered signaling pathways of cancerous cells, can be studied.
What the Primary Cells Market Looks Like?
The primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 666.0 million in 2017 at a CAGR of 8.5% from 2018–2023. Growth in the primary cells market is mainly driven by factors such as increasing cancer research; the advantages of primary human cells over cell lines; the increasing demand for monoclonal antibodies; rapid growth in the biotechnology and biopharmaceutical industries, partnerships, collaborations, and acquisitions; and increasing pharmaceutical outsourcing.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960
The Primary Cells Market is Segmented on:
1. Type
2. Origin
3. End-User
Based on type, the market is segmented into human and animal primary cells. The human primary cells segment is expected to register the highest CAGR during the forecast period owing to the high adoption of human primary cells in the development of novel cancer therapies.
On the basis of end user, the market is segmented into life science research companies and research institutes. The life science research companies segment is expected to grow at the highest CAGR during the forecast period. The high growth rate can be attributed to the high adoption of primary cells in cell-based experiments and cancer research in life science research companies as well as the increasing number of R&D facilities globally.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960
The global primary cells market is segmented by origin, type, end user, and region. By origin, the primary cells market is classified into hematopoietic, skin, gastrointestinal, liver, lung, renal, heart, skeletal & muscle, and other primary cells. The liver cells segment is expected to register the highest CAGR during the forecast period due to their increasing demand in toxicological and pharmacological studies.
Key Players:
The major players in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (Canada), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK).
Patient access solutions include software and services that help healthcare organizations to maintain their financial balance by reducing operational costs and minimizing claims rejection. These solutions are used to verify a patient’s insurance coverage eligibility, enable efficient claims processing, and manage medical necessity & denials.
The patient access solutions market is expected to reach USD 1.74 Billion by 2022 from an estimated USD 1.14 Billion in 2016, at a CAGR of 7.6%.
Regulatory compliance encouraging the use of patient access solutions, increasing patient volume and the subsequent growth in the demand for health insurance, growing importance of denials management, declining reimbursement rates, and the need to curtail escalating healthcare costs are the major factors driving the growth of the patient access solutions market. The base year considered for the study is 2016 and the forecast period includes 2017 to 2022.
Browse 62 market data Tables and 34 Figures spread through 145 Pages and in-depth TOC
Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=280473
Based on delivery mode, the patient access solutions market is classified into web & cloud-based solutions and on-premise solutions. The web & cloud-based solutions segment accounted for the largest share of the patient access solutions market in 2016. The flexibility of working from remote areas, affordability, and automated updating features are some of the factors attributing to the larger share of the web & cloud-based solutions segment
The global patient access solutions market by end user is segmented into healthcare providers, Healthcare IT outsourcing companies, and other end users. In 2016, the healthcare providers segment accounted for the largest share of the market. The high share of this segment is mainly attributed to the growing healthcare IT adoption, increasing healthcare costs, significant growth in healthcare spending worldwide, and declining reimbursement rates.
Request Sample Report of Patient Access Solutions Market: https://www.marketsandmarkets.com/requestsampleNew.asp?id=280473
Regional Growth, Development and Demand Analysis:
North America’s large share in the global market is attributed to factors such as stringent regulations, increasing government support for improving healthcare infrastructure, the need for reducing healthcare costs, increasing volume of claims denials, high number of private healthcare payers and well-established government payers, and the presence of a large number of healthcare IT companies
Key Market Players
McKesson (US), Epic Systems (US), Cerner (US), Cognizant (US), Experian plc (Ireland), Optum (US), Conifer Health (US), The Advisory Board (US), 3M (US), Craneware (UK), The SSI Group (US), ZirMed (US), Cirius Group (US), and AccuReg Software (US).
Growth in Infectious Disease Diagnostics Market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.
What the Market Looks Like?
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach $19.35 Billion in 2022, at a CAGR of 5.6%.
North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589
On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology
What Drives the Market?
The growth of the global market for infectious disease diagnostics market is primarily influenced by the following factors:
Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.
Read more about infectious disease diagnostics market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589
The geographical regions mapped in the report are:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
Some key players mentioned in the research report are:
Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific
Pune, India, 2020-Jun-05 — /EPR Network/ —
According to the new market research report "Pharmacy Automation Market by Product (Medication Dispensing System (Robot, Carousel), Packaging & Labeling System (Unit Dose, Multi Dose), Tabletop Counter, Storage System), End-User (Inpatient, Outpatient, Retail Pharmacy) - Global Forecast to 2022", published by MarketsandMarkets™, marketsandMarkets forecasts the pharmacy automation market is estimated to grow from USD 3.63 billion in 2017 to USD 5.38 Billion by 2022, at a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period.
Browse in-depth TOC on “Pharmacy Automation Market"
181 - Table
54 – Figures
218 – Pages
Get a sample PDF copy of the Report @: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890
By product, the automated medication dispensing systems segment accounted for the largest share of the pharmacy automation market
Based on product, the pharmacy automation market is segmented into automated medication dispensing systems, automated packaging and labelling systems, automated table top counters, automated medication compounding systems, automated storage and retrieval systems, and other pharmacy automation systems. Automated medication dispensing systems accounted for the largest share of the pharmacy automation market in 2016.
By end user, the retail pharmacies segment to record the highest CAGR during the forecast period
On the basis of end users the market is classified into inpatient pharmacies, outpatient pharmacies, pharmacy benefit management organization and mail order pharmacies, and retail pharmacies. Retail pharmacies is the fastest growing end user segment in the pharmacy automation market during the forecast period.
Driver: Growing need to minimize medication errors :
Medication errors and dispensing errors are recognized as leading causes of hospital readmissions across the globe. A medication error can occur due to a variety of factors such as poor order communication between the physician and pharmacist, dangerous storage practices in pharmacies, and confusion arising out of the use of similar labels. Automated systems are considered to be one of the most efficient solutions to minimize these errors.
Request Sample Report : https://www.marketsandmarkets.com/requestsampleNew.asp?id=71522890
The geographical regions mapped in the report are:
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
North America to account for the largest market size during the forecast period :
North America is expected to hold the largest market size in the pharmacy automation market during the forecast period, followed by the European region. The large share of the N+0orth American pharmacy automation market can largely be attributed to the increasing number of drug prescriptions at resulting from growth in the aging population.
Some key players mentioned in the research report are:
Becton, Dickinson, and Company (U.S.), Omnicell, Inc. (U.S.), Cerner Corporation (U.S.), Capsa Healthcare (U.S.), Parata Systems LLC (U.S), Baxter International, Inc. (U.S.), ScriptPro LLC (U.S.), KUKA AG (Germany), TCGRx Pharmacy Workflow Solutions (U.S.), RxSafe, LLC (U.S.), ARxIUM Inc. (U.S.) and Talyst Systems, LLC (U.S.).
